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Psychopharmacological Characteristics
Chemically, the drug is N-(3'dimethylamino-propyl)-iminodibenzyl hydrochloride. (16, 17) Its structural formula is reminiscent of the phenothiazine derivatives. The iminodibenzyl nucleus differs from the phenothiazine nucleus only in that the sulphur atom of the latter is replaced by a short two-carbon chain in the former. The substance is a whitish-pink crystalline powder which is water-soluble and stable under normal conditions. Its toxicity is lowest in small animals: LD so mg./kg. i.v. mouse: 38 rat: 25 rabbit: 15 Its spasmolytic action on rabbit intestine is three times that of papaverine. It has pronounced anti-serotonin activity on the guinea pig ileum but is not a potent antagonist of adrenalin or nor-adrenalin. It produces distinct potentiation of barbiturate anesthesia in the mouse.
The iminodibenzyl derivatives were originally investigated by Kuhn for their hypnotic-sedative action, which is, however, not very pronounced.
In our own psychopharmacological laboratory we found that Imipramine (G 22355) depresses or inhibits most of the perceptual, psychomotor and cognitive functions tested by our methods (18) , and, compared to neuroleptic drugs such as the phenothiazine derivatives or reserpine, Imipramine (G 22355) seems to exert more pronounced effects on the cerebral cortex.
One higher cerebral function, however, was significantly facilitated in norma] volunteers following a single dose of the drug, namely, word fluency, as tested by the ability to name as many round objects as possible in a given time. The significance of this isolated increase in verbal facility remains obscure at this stage and may be related to dosage level.
The effects of the drug on the human EEG were inconclusive in our material.
Procedure

Selection
Eighty-four patients (60 females and 24 males) were chosen on the basis of having a depressive syndrome as the principal, or at least as a prominent clinical feature.
Three-fifths of the total number fell into the broad group of 'endogenous depressions' (manic-depressive psychoses in the depressed phase, involutional melancholias). The remainder belonged to a variety of diagnostic categories (Table I) . study. Patients were rated at intervals of two weeks for the first two months and monthly thereafter, also at other times if this was indicated. An important factor in selection was the lack of observed benefit from other forms of therapy. On this basis, 41 patients who had become increasingly refractory to treatment over a number of years, and could therefore be classified as 'chronic', were nevertheless included in our sample and made up almost half of the total.
Average age was high (57 years), with a range from 20-88. One-quarter of the total were in the age group over 65 and three of these were over 80.
Dosage and Methods of Administration
Treatment was usually begun with a dosage schedule of 100 mgms. daily in four divided doses, administered by intramuscular injection. It was subsequently felt that there was little if any appreciable difference, either in efficacy or in speed of action, between the same oral and parenteral dose, and that the former could be routinely used.
Dosage was usually increased after a few days to 150 mgms daily and in a larger percentage to higher doses ranging from 200 to 600 mgms daily. The incidence of side effects increased rapidly when the daily dose exceeded 200 mgms and almost all patients were eventually kept at or below this dose.
In a small proportion of patients, it was found useful and practical to combine Imipramine (G 22355) therapy with other phrenotropic drugs such as hypnotics or neuroleptic agents, e.g. chlorpromazine.
Methods of Assessment
Clinical Judgment and Rating Scale
Recognizing the limitations of a double blind procedure, we decided to evaluate the drug first by relying on our clinical judgment. In order to reduce individual differences in assessment, a rating scale (Table II) was devised for the ad hoc purpose of evaluating the intensity of the depressive symptoms. Each patient was rated independently by two psychiatrists prior to the administration of the drug. It was soon established that the differences between the two raters were insignificant, hence this scale was used throughout the four months of this CANA!:IAN FSYCHIATRIC ASSOCIATION JOURNAL Vol. 3, No.4 Using this rating scale, we evaluated our results in terms of the percentage change in the individual patient's score. As base line we took the total score obtained before commencement of therapy. A 95-100 per cent reduction of the score was classified as 'Recovered', which meant that these patients had no residual evidence of depression, or practically none. A 50-95 per cent reduction of the score was classified as 'Much Improved', and these patients were generally considered to be well enough to leave the hospital. A 10-50 per cent reduction of the score was classified as 'Improved'; these patients' symptoms were reduced but not to the point where they could leave the hospital. The range of minus to plus 10 per cent change in the initial score was classified as 'Unimproved'; and an increase of the score of more than 10 per cent was classified as 'Worse'.
We found that the evaluation by means of the rating scale corresponded very closely to the usual clinical assessment by other methods, that is to say: interviews with patients, reports by nurses and other hospital personnel, reports from relatives and eventually trial discharge from the hospital.
Not all patients in the 'Recovered' and 'Much Improved' categories have actually left the hospital. Some will be leaving within the next month or so, some have other conditions necessitating further hospitalization (e.g. neurotic overdependency, schizophrenia), and some are difficult to rehabilitate owing to lack of community resources.
It was of course realized that our rating scale could not be used to assess all the signs and symptoms of depression, but our intention was to evaluate quickly and efficiently the cardinal features.
Double-Blind Experiment
When the therapeutic trial was in full progress, we decided to make a partial check on our results, employing a double-blind procedure. At that time, 42 patients were receiving the drug. These patients were divided into two groups of 21 each, one for continuation of the drug, the. other for placebo (same dose). We decided to administer the placebo tablets for two weeks, assuming that this was a sufficiently long period of time for differences betwen the drug and placebo group to become apparent. The hospital pharmacist was asked to choose at random the names of patients for either group, to label the bottles containing the tablets with the name of each patient, and to issue the 42 bottles to the ward nurses. He kept the code, which was broken after the two weeks. All the patients were rated according to the rating scale before the beginning of placebo study, and again before the code was broken. Table III shows the cumulative results obtained according to our rating scale.
Results of Clinical Rating
Few patients recovered completely within two weeks of commencement of therapy, but about a quarter were much improved. Another quarter were unimproved or worse. Some of the latter developed complications, not necessarily serious ones, nevertheless it seemed wiser to discontinue treatment (see below).
After four weeks, the recovery rate had doubled; improvement was sustained and only two more patients had reacted unfavourably.
The greatest improvement in our sample occurred between the fourth and eighth week of therapy. By the end of the eighth week, nearly a quarter of all the patients had recovered, two-fifths were much improved, another quarter improved somewhat, and only 15 per cent showed no improvement; the latter fi~re includes those patients whose treatment had been discontinued early for vanous reasons. October, 1958 TREATMENT OF DEPRESSION BY IMIPRAMINE At the end of the four months' period of investigation, the recovery rate was 30 per cent, and the unimproved rate was only 10 per cent.
It must be mentioned here that the results four weeks after commencement of therapy should have been better than indicated in Table III . This statement is based on the fact that several patients who initially improved relapsed when therapy was interrupted after approximately two weeks, and again improved when therapy was resumed; the period of interruption of therapy was usually just a few days, or two weeks at the most. Thus, the four weeks' scores reflect these patients' condition just after therapy had been resumed, before the full effect was obtained. At the beginning of this investigation, we decided to discontinue therapy if the patients had shown a good response within two weeks. Many of these patients subsequently relapsed within the following two weeks; hence they were given a second and usually longer course, to which they usually responded within a few days.
Three patients did not improve while receiving Imipramine (G 22355), but subsequently improved with KC.T.
The optimum time for discontinuing therapy has not yet been determined. Several patients maintained their improvement with only 2-3 weeks of therapy, while most patients in our series required at least a month of therapy, and some seem to require maintenance therapy for as yet an indefinite period of time.
A further breakdown according to diagnostic categories shows that the best results were obtained in patients diagnosed as having endogenous depressions; about three-quarters of these cases were judged recovered or much improved. Patients with diagnoses of neurotic depressive reactions responded less favourably, as was to be expected. Of the eleven patients whose diagnosis was schizophrenia or schizo-affective psychosis, and who were treated because depressive elements were present in their condition, none recovered, four were much improved, six were improved, and one was worse.
Of 19 patients with chronic endogenous depression, nine recovered or were much improved, and only three were unchanged; eleven of this group had been found to be refractory to E.C.T., and of these four were much improved and five improved. On the whole, our results were similar to those reported by Kuhn; 75-80 per cent of his 300 patients improved, those with endogenous depressions showing a better response than depressed schizophrenics, neurotics, and others.
Results of Double-Blind Experiment
Of the patients on placebo, ten became worse, eleven did not. Of the patients on active drug, three became worse, and 17 did not (one dropped out for administrative reasons). This difference is significant statistically « 0.05). Of the three patients who became worse while receiving the drug, one was diagnosed 'Inadequate Personality with Depressive Features' and had a previous history of frequent fluctuations of mood; the other two were both typical 'chronic schizophrenics' who at the time of initial selection for therapy with the drug, had some depressive features. All of the ten patients who became worse on placebo improved within two weeks of resumption of therapy with the active drug. None of the patients who remained improved or unchanged while receiving placebo, became worse afterwards.
Side Effects
A variety of side effects was encountered in about one-third of all patients treated.
Cardiovascular and vasomotor symptoms were the most frequent, comprising eleven cases of syncope or hypotension and one case of dyspnea and cyanosis, the latter promptly relieved by a reduction in dosage from 200 to 100 mgms daily. One case of fatal myocardial infarction in the series may possibly have been related to the drug, although there was no direct evidence of this. This patient was showing an excellent clinical response to Imipramine (G 22355) when, on the twentieth day of treatment, he died suddenly while eating his supper.
Other serious side effects included epileptiform seizures in two patients (one of these had a past history of epilepsy, while the other had a characteristic EEG). Diplopia occurred in two other patients, jerky tremors in six, and involuntary staring was noted in four. None of the patients developed extrapyramidal symptoms of the akinesia or akathisia type, but one case of dystonia with a marked lordosis was probably of extrapyramidal origin.
Psychiatric complications included visual hallucinations in five cases, increased agitation in three, and a shift to hypomanic excitement in two.
Less serious symptoms such as tremor, increased sweating, and dry mouth were fairly common, and in many cases, were not considered worth reporting by the affected patients.
One out-patient (not included in this series) developed asymptomatic jaundice but recovered from this in about ten days after Imipramine (G 22355) was discontinued. Kuhn also reports two cases of transient jaundice in his series of 300 cases.
We did not observe the photosensitization which Kuhn described in his patients (ours may have been protected by a period of weak sunlight), nor were other dermatological complications reported in this series.
Spot tests of blood urea nitrogen, alkaline phosphatase and serum bilirubin, as well as routine analyses of blood and urine, were performed on a number of patients throughout the period of investigation and did not reveal any deviation from normal. This is also in accord with Kuhn's findings.
In our analysis of the group suffering from side effects, age and dosage were found to be contributory factors.
Of the 20 patients aged over 65, more than half had side effects (compared with the incidence of one-third in the total group).
Serious side effects could have been practically eliminated except in elderly patients if the daily dose of Imipramine (G 22355) had been kept below 200 mgms, and when side effects did occur they tended to be promptly relieved by stopping or decreasing the drug.
It is our impression that a daily dosage below 200 mgms is sufficient, except in a few cases, to produce optimum therapeutic benefit, although the rate of improvement may be somewhat slower.
Discussion
The first question a clinical investigator of a new drug must ask himself when looking at his results deals with the grounds for his assumption that these results are attributable to the pharmacological effects of the drug and not to incidental and environmental factors. In our case this assumption is based on two lines of evidence.
First, our clinical judgment indicated that the proportion of patients significantly improved following the administration of the drug was greater than could have been anticipated as spontaneous improvements occurring in the natural history of the illness or as placebo effects. Many of the patients had been chronically ill and had failed to respond to other treatments, and most acute cases under treatment improved in a shorter time than is usually observed in endogenous depressions left to their own resources. Patients suffering from endogenous depressions are known to be particularly resistant to placebo effects.
Secondly, our double-blind technique brought out a higher relapse rate of patients on placebo than of patients on the active drug. This difference was statistically significant.
Although we can be reasonably sure that the degree of improvement shown by our depressed patients on this drug in a given time was greater than could have been expected without a drug or with an inactive substance, we are unable at this stage to express any opinion on the specificity of the pharmacological action of Imipramine (G 22355). It is conceivable that similar results might have been obtained with other drugs. We are simply reporting our results with this drug as they were observed in our systematic study of its action on depressed patients.
Our findings indicate that this substance is of value in the treatment of depressed patients. It should be noted, however, that the effects of the drug are much less spectacular than the therapeutic action of electroconvulsive treatment as regards both immediacy and intensity of its results. A deeply depressed patient who is suicidal might still require electroconvulsive therapy in order to control the situation rapidly, particularly if the patient is not hospitalized. In the setting of a closed hospital we were able to give effective relief to most of our depressed patients with the drug alone, even if they were greatly disturbed. There are certain advantages to a therapeutic regime without electroconvulsive treatments. On the other hand, psychiatric tolerance to depressive symptoms in patients has been so much reduced during the last fifteen years that many psychiatrists may find it difficult to wait two to four weeks before seeing a definite lifting of depression in their patients.
Imipramine (G 22355) has to be given for some time after most symptoms have subsided and, including this maintenance therapy, the treatment period may often be longer than with electroconvulsive treatment. The fact that some patients seem to develop tolerance to the drug and that it produces no particularly unpleasant side effects raises the question of possible addiction, a question that we can not answer at the present time other than by stating that we did not observe any tendency for any patient to become dependent on the drug, nor any withdrawal symptoms in our group of patients.
A brief discussion of the term 'depression' might be in place here, as the varying use of this diagnostic term by different authors has at times caused some semantic confusion. It is perhaps unfortunate that the term 'depression' is used by physiologists and by psychiatrists in quite a different sense. The physiologist refers to depression as a simple reduction, a passive partial loss of function, as in circulatory and respiratory depression. The psychiatrist, on the other hand, when he speaks of depression as a diagnostic category refers to a 162 CANADIAN PSYCHIATRiC ASSOCIATION JOURNAL Vol. 3, No.4 complex state of highly organized emotional and ideational processes which are characterized by the quality of their special configuration, rather than by their reduced level of intensity. In fact, many vital processes of the patient in a state of psychiatric depression are often greatly heightened in intensity (14, 19) e.g. reflex irritability, blood pressure, adrenocortical activity, basal metabolism, affective tone, level of arousal, even if we are dealing with a patient in a retarded and not in an agitated depression.
By confusing the apparent lack of energy of the patient in a psychiatric depression with the true energy deficit which exists in patients whose functions are depressed in the physiological sense of the term, the misleading notion of 'energizers', i.e. agents which make available additional energy for the psychiatrically depressed patient, has developed. This notion is misleading because a freeing and redirection of energy is needed in the psychiatrically depressed patient, rather than an additional supply of it. The whole concept of psychic energy is far from clear, as we have pointed out in a previous publication. (14) . The foregoing remarks apply only to the special category of depressed patients such as we have selected for a therapeutic trial with Imipramine (G 22355). Since other types of psychiatric patients have sometimes been included in the diagnostic classification 'depression', we propose the following subdivision of psychiatric patients who are all characterized by the common denominator of reduced spontaneity. If we accept to refer to all such patients as 'depressed', we would have to distinguish between the depression of the patient in coma and sopor, who is on the lower end of the scale of arousal, the asthenic depression of the patient with a true reduction of vital energy as in fatigue and exhaustion states, the apathetic depression of the patient with a primary lack of drive as in some inert schizophrenics, the catatonic depression of the patient with cataleptic symptoms or withdrawal due to a defensive inhibition of drive, and finally, the dysphoric depression. Dysphoric depression is the only type we have considered in our therapeutic trial, i.e. the psychiatric depression characterized by an affect of despondency, bitterness or morbid guilt, and the corresponding physiognomic, behavioural and ideational manifestations.
It is interesting to note that the iminodibenzyl derivative which we employed is characterized by its primarily inhibitory or depressing (in the physiological sense) action on the central nervous system. Iproniazid, another therapeutically effective agent in depressive conditions, is a drug with mainly excitatory action on the central nervous system. It is not surprising that sedative as well as stimulant drugs may be effective in a psychiatric depression of the dysphoric type, if one keeps in mind that this is a complex condition and not simply the result of global inhibition or excitation of the eN.S. One could speculate that some particular regulatory center, probably subcortically located in the brain, is either pathologically inhibited, depressed or excited in relation to the surrounding neuronal field, and that a therapeutically effective drug restores the disturbed equilibrium of excitatory gradients either by direct influence on the disturbed focus, ?r in~ire~t!y> by actin&, .on the surr?unding cerebral field; hence it may have either inhibiting or excltmg properties. Such a speculation can not be substantiated at this time, arid is only offered as a possible conceptual model.
Considering the biochemical properties of Imipramine (G 22355) as contrasted to iproniazid, one notes that Imipramine (G 22355) has an appreciable anti-serotonin action, while iproniazid through its inhibition of the enzyme monoamino-oxidase probably increases the serotonin level in the brain. (20, 21) This increase of cerebral serotonin has been proposed as an explanation for the anti-depressant effect (in the psychiatric sense) of iproniazid. If this theory is correct, it follows from the therapeutic action of Imipramine (G 22355) that other mechanisms must be involved, as well, in the effective treatment of psychiatric depressions of the dysphoric type. Summary 1. Imipramine (G 22355) is a new chemical agent with a primarily inhibitory action on the central nervous system. It has definite anti-depressive properties in the psychiatric sense, producing a gradual lessening and frequently a disappearance of the symptoms and signs of depressive states.
2. Of 84 patients with various psychiatric diagnoses who had in common the presence of symptoms of dysphoric depression, 30 per cent recovered or were much improved after two weeks, and 60 per cent recovered or were much improved after eight weeks of therapy with Imipramine (G 22355); a further percentage showed lesser degrees of improvement. These findings correspond fairly well to the results reported by Kuhn in 300 patients, viz. improvement in three-quarters to four-fifths of his cases.
3. The results in depressed patients with neuroses, schizophrenia, and organic conditions were less favourable than in patients with endogenous depressions.
4. The frequency of side effects was low, but increased when the dose was over 200 mgms. daily, especially in patients over the age of 65. Side effects were expressed mainly in disturbed functioning of the autonomic nervous system, although there were also a few cases of toxic confusion, two cases with epileptiform seizures, and one case of mild transient jaundice. There was one death in our series, probably due to acute coronary occlusion and apparently not related to the drug. 5. A rating scale for the rapid and effective assessment of depressive symptoms is described, and the results of a 'double-blind' experiment are discussed.
6. The concepts of physiological and psychiatric depression are discussed and several clinical categories are differentiated in order to clarify the use of the term.
7. It is concluded that Imipramine (G 22355) is a relatively non-toxic drug useful in the treatment of depressions, especially of the endogenous type.
